Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
Authors:
- Bruce NealBruce Neal
- Vlado PerkovicVPVlado Perkovic
- Dick de ZeeuwDZDick de Zeeuw
- Kenneth W. MahaffeyKMKenneth W. Mahaffey
- Greg FulcherGFGreg Fulcher
- Peter SteinPSPeter Stein
- Mehul DesaiMDMehul Desai
- Wayne ShawWSWayne Shaw
- Joel JiangJJJoel Jiang
- Frank VercruysseFVFrank Vercruysse
- Gary MeiningerGMGary Meininger
- David MatthewsDMDavid Matthews
Open Access
- 1 August 2013
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 166 (2) , 217-223.e11
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 DiabetesDiabetes Care, 2012
- Risk of Bladder Cancer Among Diabetic Patients Treated With PioglitazoneDiabetes Care, 2011
- Glucose handling by the kidneyKidney International, 2011
- Renal glucose reabsorption inhibitors to treat diabetesTrends in Pharmacological Sciences, 2011
- Rosiglitazone: what went wrong?BMJ, 2010
- Intensive glucose control and macrovascular outcomes in type 2 diabetesDiabetologia, 2009
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non–Insulin-Dependent DiabetesDiabetes, 2005
- Maximum Tubular Reabsorption Capacity for Glucose and Renal Hemodynamics during Rapid Hypertonic Glucose Infusion in Normal and Diabetic SubjectsScandinavian Journal of Clinical and Laboratory Investigation, 1971